Gyre Therapeutics (NASDAQ:GYRE) Posts Earnings Results, Misses Estimates By $0.06 EPS

Gyre Therapeutics (NASDAQ:GYRE) issued its quarterly earnings data on Friday, August 7th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06), FiscalAI reports. Gyre Therapeutics had a negative net margin of 15.47% and a negative return on equity of 6.57%. The firm had revenue of $29.11 million for the quarter, compared to analysts’ expectations of $26.49 million.

Gyre Therapeutics Trading Up 3.7%

Shares of NASDAQ:GYRE opened at $6.68 on Wednesday. Gyre Therapeutics has a 12 month low of $5.44 and a 12 month high of $9.42. The company has a 50-day moving average price of $6.45 and a 200 day moving average price of $6.96. The company has a market cap of $744.89 million, a price-to-earnings ratio of -31.81 and a beta of 1.92.

Institutional Investors Weigh In On Gyre Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its stake in shares of Gyre Therapeutics by 28.8% in the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after purchasing an additional 1,402 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Gyre Therapeutics by 84.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after buying an additional 2,961 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Gyre Therapeutics by 77.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after buying an additional 3,244 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in Gyre Therapeutics in the fourth quarter worth $77,000. Finally, Wells Fargo & Company MN boosted its stake in Gyre Therapeutics by 132.4% during the fourth quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock worth $91,000 after buying an additional 7,361 shares during the period. 23.99% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

GYRE has been the subject of a number of research reports. Zacks Research lowered Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gyre Therapeutics in a research note on Friday, August 7th. Finally, Wall Street Zen cut Gyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus target price of $16.00.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.